Bertoli L, Fusco M, Micallef E, Busnardo I
J Hypertens Suppl. 1985 Nov;3(2):S153-4.
The effects of captopril have been studied in 10 patients suffering from chronic obstructive pulmonary disease (COPD) with moderate essential hypertension. Captopril was given as monotherapy (75-100 mg/day) over a period of 60 days. The following effects of captopril were seen in these patients: a significant reduction of systolic blood pressure (P less than 0.01) and of diastolic blood pressure (P less than 0.001), both in the supine and in the standing position; a significant increase of the vital capacity (P less than 0.05); no significant change in other various respiratory function tests or of heart rate, and no side effects, including bronchospasm in the patients sensitive to bronchodilator drugs. The present data suggest that in COPD patients with essential hypertension, captopril is an effective hypotensive agent and has no adverse effects in pulmonary function.
已对10例患有中度原发性高血压的慢性阻塞性肺疾病（COPD）患者研究了卡托普利的效果。卡托普利作为单一疗法给药（75 - 100毫克/天），为期60天。在这些患者中观察到卡托普利有以下效果：仰卧位和站立位时收缩压（P < 0.01）和舒张压（P < 0.001）均显著降低；肺活量显著增加（P < 0.05）；其他各种呼吸功能测试或心率无显著变化，且无副作用，包括对支气管扩张剂药物敏感的患者未出现支气管痉挛。目前的数据表明，在患有原发性高血压的COPD患者中，卡托普利是一种有效的降压药，对肺功能无不良影响。
